B. Gülave

High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors

S. Teerenstra, L. Rodwell, B. Fabriek, 2021, ESMO open.

The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells

E. D. de Lange, M. Hirasawa, J. Elassaiss-Schaap, 2022, European Journal of Pharmaceutical Sciences.

Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?

B. Gülave, Mohammed A A Saleh, E. D. De Lange, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Does nonlinear blood-brain barrier transport matter for morphine dosing strategies?

B. Gülave, Mohammed A A Saleh, E. D. De Lange, 2023, bioRxiv.

Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling

Y. Wong, P. Graaf, W. V. D. Brink, 2016, The AAPS Journal.

Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in Mice.

C. Stewart, J. Elassaiss-Schaap, O. Campagne, 2023, Pharmaceutical research.